Editas Medicine's Linda Burkly acquires 16,533 shares

The performance-based award underlying the vesting was originally granted on March 2, 2024.

Available on EDGAR 11/06/2026 - 04:36 PM EST Accepted by SEC EDGAR 11/06/2026 - 04:36 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Editas Medicine, Inc. reported that Linda Burkly, EVP, Chief Scientific Officer, acquired 16,533 shares of common stock on November 5, 2026, through vesting of part of a performance-based restricted stock unit award after achievement of a specified research and development milestone. Her directly held common stock position following the transaction was 78,193 shares.

Insider Trade Summary

Grant/Award: 16,533 shares

Grant/Award 1 txn

Insider Burkly Linda

Role EVP, CHIEF SCIENTIFIC OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	16,533	$0.00	$0.00

Holdings After Transaction: Common Stock — 78,193 shares (Direct)

Holdings Before and After: Common Stock, 61,660 to 78,193 shares (Direct)

Footnotes (1)

1. F1. Reflects the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on March 2, 2024.

Key Figures

Shares acquired: 16,533 shares Direct common stock holdings after transaction: 78,193 shares Transaction date: November 5, 2026 +1 more

4 metrics

Shares acquired 16,533 shares November 5, 2026

Direct common stock holdings after transaction 78,193 shares Following the November 5, 2026 transaction

Transaction date November 5, 2026 Vesting of part of a performance-based restricted stock unit award

Original award grant date March 2, 2024 Performance-based restricted stock unit award

Key Terms

performance-based restricted stock unit award, vesting, research and development milestone

3 terms

performance-based restricted stock unit award financial

"a portion of a performance-based restricted stock unit award"

A performance-based restricted stock unit award is a promise to give company shares to an employee or executive only if the business hits specific targets over a set period. Think of it as a conditional prize that vests like a savings plan: if agreed goals (such as revenue, profit, or stock performance) are met, the recipient receives the shares; if not, they get nothing. Investors pay attention because these awards align management incentives with company results and can affect share count, future earnings and executive behavior.

vesting financial

"Reflects the vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

research and development milestone technical

"achievement of a specified research and development milestone"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EDIT shares did Linda Burkly acquire?

Linda Burkly acquired 16,533 shares of Editas Medicine common stock on November 5, 2026, through vesting of part of a performance-based restricted stock unit award. Vesting followed achievement of a specified research and development milestone; her directly held position after the transaction was 78,193 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burkly Linda

(Last) (First) (Middle)

11 HURLEY ST.

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF SCIENTIFIC OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2026		A(1)		16,533	A	$0	78,193	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on March 2, 2024.

Remarks:

	/s/ Linda C. Burkly	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)